A detailed history of Privium Fund Management B.V. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 119,000 shares of RXRX stock, worth $784,210. This represents 0.18% of its overall portfolio holdings.

Number of Shares
119,000
Previous 78,000 52.56%
Holding current value
$784,210
Previous $514,000 56.42%
% of portfolio
0.18%
Previous 0.13%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025

BUY
$5.7 - $8.27 $233,700 - $339,070
41,000 Added 52.56%
119,000 $804,000
Q3 2024

Nov 01, 2024

BUY
$5.92 - $8.6 $153,920 - $223,600
26,000 Added 50.0%
78,000 $514,000
Q2 2024

Jul 31, 2024

BUY
$7.35 - $10.05 $382,200 - $522,600
52,000 New
52,000 $390,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.19B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Privium Fund Management B.V. Portfolio

Follow Privium Fund Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Privium Fund Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Privium Fund Management B.V. with notifications on news.